Inhibitory potential against oral squamous cancer cells demonstrated by amyloid beta peptide (s)/doxorubicin (DOX) conjugates
Saved in:
| Main Author: | Rethinam Senthil |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Oral Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024001900 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Helping anti-cancer activity of cetuximab (Erbitux) by monoclonal antibody conjugated nanocurcumin - In vitro studies on human oral squamous carcinoma cell line (OECM)
by: Rethinam Senthil, et al.
Published: (2024-03-01) -
PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer
by: Bingting Li, et al.
Published: (2023-12-01) -
The effects of peptide IF7-conjugated dendrimer loaded with doxorubicin on colorectal cancer
by: Omid Reza Tamtaji, et al.
Published: (2025-03-01) -
Curcumin-infused carboxymethyl cellulose–gelatin gel for oral tissue repair: Preliminary evaluation
by: Senthil Rethinam
Published: (2025-11-01) -
Doxorubicin (DOX) modified zinc oxide (ZnO) nanocomposite encapsulated with polymethyl methacrylate (PMMA) biopolymer for effective cancer treatment
by: Abinash Das, et al.
Published: (2025-01-01)